Medicus Pharma

MDCX

市值 US$466萬

Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update marking its third anniversary.  The Nasdaq-listed biotech said its priorities are to advance selected clinical and regulatory milestones, align organizational costs with those priorities, and pursue licensing and co-development opportunities.

PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug development.

Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced prostate cancer patients at increased cardiovascular risk.  The company said the stage-gated design starts with about 80 randomized patients, replacing a previously FDA-cleared, stand-alone 40-patient open-label dose-optimization study.

Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy

Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular basal cell carcinoma. The decision builds on the company's portfolio strategy announced earlier this month, under which Medicus is concentrating resources on programs offering the most compelling risk-adjusted opportunity.

PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. Bokhari said final SkinJect results published on ClinicalTrials.gov had confirmed the 200-microgram patch as the dose to be taken forward into further registrational studies.

Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its next-stage registrational trial in a rare genetic skin cancer syndrome. The randomized, double-blind, multicenter trial enrolled patients across 10 US investigative sites, comparing two dose levels of SkinJect against a device-only microneedle comparator.

CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma

Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors, the company said Tuesday. CD228V is now the company's principal strategic priority, with initial development focused on establishing clinical proof-of-concept in a selected tumor population.